Skip to main content
Figure 1 | Journal of Ovarian Research

Figure 1

From: Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3

Figure 1

Acquired trastuzumab-resistant cell line SKOV3-T cells grow faster than SKOV3. SKOV3 cells were cultivated for 8 months in the presence of 20 μg/ml trastuzumab continuously to obtain SKOV3-T cells. The comparison of SKOV3-T and parental SKOV3 cells by (A) cell proliferation, (B) cell counting, (C) agar clone formation, (D) transwell, and (E) in vivo carcinogenic assays. In cell counting assays, cells were cultured in day 0 at the start concentration of 1 × 104 per 24-well, and in day 1 to day 6, the cells were digested everyday and the whole cell number was counted. The trastuzumab-resistant SKOV3-T seemed to have significantly enhanced cell growth/proliferation, clone formation, stronger invasion and migration character both in vitro and in vivo versus non-resistant SKOV3 cells.

Back to article page